Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.54 |
| ▸ | EP300 | Q09472 | 2/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735879 | 0.85 | BRD4 (0.51) | BRD4HSPB1 | |
| SCHEMBL16651036 | 0.84 | BRD4 (0.48) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16660689 | 0.84 | BRD4 (0.59) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16868381 | 0.84 | BRD4 (0.58) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159992 | 0.83 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16333294 | 0.83 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL28880313 | 0.81 | BRD4 (0.50) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16658392 | 0.81 | BRD4 (0.55) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16651491 | 0.81 | BRD4 (0.55) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20160100 | 0.77 | BRD4 (0.60) | BRD4EP300BRD2ADORA2BTSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041253-B | Pyridine N-oxide derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-109836385-B | Tetrahydroquinoline N-oxide derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-110198941-B | Pyrrolopyridine N-oxide derivative and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | BRD4 3241/4885EP300 1615/4885BRD2 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.